ReviewCellular and molecular neurobiology1994
Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.
Review in Cellular and molecular neurobiology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Computational genes: a tool for molecular diagnosis and therapy of aberrant mutational phenotype.BMC bioinformatics · 2007Article
- The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides.Biomaterials · 2002Review
- Investigating the mechanisms of retinal degenerations with antisense oligonucleotides.Documenta ophthalmologica. Advances in ophthalmology · 2001Article
- Gene interference using antisense oligodeoxynucleotides on whole chick embryos. Optimal ring and roller-bottle culture technique.Molecular biotechnology · 2000Article
- Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance.Cytotechnology · 1998Article
- Strategy for designing specific antisense oligonucleotide sequences.Journal of gastroenterology · 1997Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. Synthetic oligonucleotides can inhibit the expression of a gene in a sequence specific manner on the transcriptional and translational level. These molecules are usually referred to as antisense oligonucleotides. 2. Antisense mediated inhibition of gene expression is a valuable tool to analyze the function of a gene in vivo and can also be used for therapeutic gene suppression. 3. A number of factors such as the mode of action, specificity, chemistry, and pharmacology must be carefully considered for the design and successful application of antisense oligonucleotides. 4. Assay systems and controls must be chosen as to assure that the observed biological effects of antisense oligonucleotides do in fact reflect the result of a specific gene inhibition. 5. This article critically discusses these factors in view of the literature and our own experience with a wide range of cell types and animal models, targeting different genes. The emphasis is on the use of phosphorothioate oligodeoxynucleotides in cell cultures, in vivo, and as potential drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.